Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In December 2020 Sterling made a significant investment in ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation, and is working towards completing a full acquisition by the end of Q1 2021. Together, as Sterling Pharma Solution, the teams will develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.